Fluoropyrimidine Therapy in Gastrointestinal Cancer: Balancing Survival Benefits and Cardiotoxicity Risks.
作者信息
Sonbol Mohamad Bassam, Bekaii-Saab Tanios, Larsen Carolyn M
机构信息
Hematology and Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona, USA.
Hematology and Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona, USA.
出版信息
JACC CardioOncol. 2025 Jun;7(4):357-359. doi: 10.1016/j.jaccao.2025.02.006. Epub 2025 Apr 8.
Abstract
摘要
相似文献
1
Fluoropyrimidine Therapy in Gastrointestinal Cancer: Balancing Survival Benefits and Cardiotoxicity Risks.
JACC CardioOncol. 2025 Jun;7(4):357-359. doi: 10.1016/j.jaccao.2025.02.006. Epub 2025 Apr 8.
2
Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer.
JACC CardioOncol. 2025 Jun;7(4):345-356. doi: 10.1016/j.jaccao.2025.01.019. Epub 2025 Apr 8.
3
Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
Crit Rev Oncol Hematol. 2021 Jun;162:103346. doi: 10.1016/j.critrevonc.2021.103346. Epub 2021 Apr 27.
4
Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
Cardiovasc Toxicol. 2022 Feb;22(2):130-140. doi: 10.1007/s12012-021-09708-4. Epub 2021 Nov 18.
5
5-fluorouracil and cardiotoxicity: a review.
Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140. doi: 10.1177/1758835918780140. eCollection 2018.
6
Cardiotoxicity induced by fluoropyrimidine drugs in the treatment of gastrointestinal tumors.
World J Gastrointest Oncol. 2024 Feb 15;16(2):251-254. doi: 10.4251/wjgo.v16.i2.251.
7
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Curr Oncol Rep. 2022 Jul;24(7):943-950. doi: 10.1007/s11912-022-01256-6. Epub 2022 Mar 26.
8
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
ESMO Open. 2022 Jun;7(3):100427. doi: 10.1016/j.esmoop.2022.100427. Epub 2022 Mar 30.
9
A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
J Oncol Pharm Pract. 2023 Dec;29(8):1951-1956. doi: 10.1177/10781552231161822. Epub 2023 Mar 7.
10
Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity.
Onco Targets Ther. 2020 Oct 9;13:10197-10206. doi: 10.2147/OTT.S264156. eCollection 2020.
本文引用的文献
1
Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer.
JACC CardioOncol. 2025 Jun;7(4):345-356. doi: 10.1016/j.jaccao.2025.01.019. Epub 2025 Apr 8.
2
Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis.
BMC Cancer. 2024 Sep 30;24(1):1210. doi: 10.1186/s12885-024-12981-5.
3
Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).
Acta Oncol. 2024 May 2;63:248-258. doi: 10.2340/1651-226X.2024.24023.
4
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
ESMO Open. 2023 Apr;8(2):101199. doi: 10.1016/j.esmoop.2023.101199. Epub 2023 Apr 3.
5
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm.
PLoS One. 2022 Apr 7;17(4):e0265767. doi: 10.1371/journal.pone.0265767. eCollection 2022.
6
How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain: A Single Center Approach.
JACC CardioOncol. 2020 Nov 17;2(4):650-654. doi: 10.1016/j.jaccao.2020.06.012. eCollection 2020 Nov.
7
Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease.
J Mol Cell Cardiol. 2021 Dec;161:98-105. doi: 10.1016/j.yjmcc.2021.07.004. Epub 2021 Jul 21.
8
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm.
JACC CardioOncol. 2021 Mar;3(1):101-109. doi: 10.1016/j.jaccao.2020.12.005. Epub 2021 Mar 16.
9
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Clin Colorectal Cancer. 2019 Mar;18(1):52-57. doi: 10.1016/j.clcc.2018.09.006. Epub 2018 Oct 10.
10
5-fluorouracil and cardiotoxicity: a review.
Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140. doi: 10.1177/1758835918780140. eCollection 2018.
Zotero 插件